Important limitations with the at present accessible antidepressant therapy techniques have inspired investigation on discovering new and additional effective drugs to treat depression. Cannabidiol ( CBD) is a non-psychotomimetic element of Cannabis sativa, and emerges in this regard as a promising compound. In 2010, we had been the very first laboratory to demonstrate that CBD is successful in animal models of predictive of antidepressant impact, a discovering now confirmed by many other groups. Current proof suggests that CBD promotes each a speedy and a sustained antidepressant impact in animal models. CBD has a complicated pharmacology, with the capacity to interact with numerous neurotransmitter systems involved in depression, which includes the serotonergic, glutamatergic, and endocannabinoid systems. Furthermore, CBD induces cellular and molecular adjustments in brain regions associated to depression neurobiology, such as enhanced Brain Derived Neurotrophic Issue (BDNF) levels and synaptogenesis in the medial prefrontal cortex, as effectively as it increases neurogenesis in the hippocampus. This evaluation presents a extensive essential overview of the present literature associated to the antidepressant effects of CBD, with concentrate at the probable mechanisms. Ultimately, challenges and perspectives for future investigation are discussed.
Copyright © 2019 Elsevier B.V. All rights reserved.